1. Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results

3. Program Goals

4. T2DM and Patients at CV Risk

5. A Personalized Approach to Glycemic Targets in the Context of CV Risk

6. CV Risk and Established Oral Antihyperglycemics

7. Effect of Metformin on CV Risk Factors: the GIPS-III Trial

8. AEs Associated With TZDs in T2DM

9. December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

10. SAVOR-TIMI 53 (Saxagliptin): Hospitalization for HF

11. EXAMINE (Alogliptin): Hospitalization for HF[a,b]

12. TECOS (Sitagliptin): Hospitalization for HF

13. EMPA-REG OUTCOME: Trial Design

14. EMPA-REG: Primary Outcome (3-Point MACE) CV Death, Nonfatal MI, or Nonfatal Stroke

15. EMPA-REG: Results for CV Death

16. EMPA-REG: Hospitalization for HF

17. ELIXA (Lixisenatide): Primary Outcome CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for UA

18. LEADER (Liraglutide): Study Design

19. LEADER: Primary Outcome*

20. LEADER: CV Death

21. LEADER: Time to Nonfatal MI and Nonfatal Stroke

22. LEADER: Hospitalization for HF

23. LEADER: Microvascular Outcomes

24. What Explains the Macro- and Microvascular Improvements Observed in LEADER?

25. LEADER: Overall Summary of AEs

26. LEADER: AEs Leading to Permanent Treatment Discontinuation

27. LEADER: Risk for Hypoglycemia

28. Intensive Glycemic Control Increased All-Cause Mortality (ACCORD)[a]

29. Association of T2DM With 6 Common CVDs/Events

30. Conclusions

31. Abbreviations

32. Abbreviations (cont)